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We describe a case series of 17 patients hospitalized 
in Manaus (western Brazilian Amazon) with PCR-conﬁ  rmed 
Plasmodium vivax infection who were treated with chloro-
quine and primaquine. The major complications were jaun-
dice and severe anemia. No in vivo chloroquine resistance 
was detected. These data help characterize the clinical pro-
ﬁ  le of severe P. vivax malaria in Latin America. 
D
uring 2000–2007, in Latin America, a total of 
7,554,993 cases of malaria were recorded; 5,507,167 
(72.9%) of these cases were caused by Plasmodium vivax 
parasites. Of the P. vivax malaria cases, 3,833,477 were re-
ported in Brazil, mainly in the Amazon Region (1). Ofﬁ  cial 
data from the Brazilian Ministry of Health identify Manaus 
as one of the leading cities in terms of number of P. vivax 
malaria cases in Latin America (2).
Manaus (population 1,738,641 in 2009), the capital of 
the state of Amazonas in the western Brazilian Amazon, 
is clearly part of a new frontier in the economic develop-
ment of the Amazon. In 2009, a total of 19,698 cases of 
malaria were reported in Manaus (annual parasitary index 
11.3/1,000 population; 92.6% caused by P. vivax). Since 
the mid-1990s, as P. vivax was becoming the predominant 
malaria species in Brazil (3), severe cases and even deaths 
attributable to P. vivax infection have been reported anec-
dotally (3). A concomitant trend of increased hospitaliza-
tion of P. vivax–infected patients was seen in a Manaus 
tertiary care center (4).
In 2000, one of the authors noted the increased clinical 
severity of P. vivax cases seen in this same hospital; the 
frequency of hospitalization was very similar to that of pa-
tients infected with P. falciparum (M.G.C.A., unpub. data). 
Other reports from the same reference center in Manaus 
have been published regarding unusual complications 
of P. vivax infection, such as severe rhabdomyolysis (5) 
and immune thrombocytopenic purpura (6). At the same 
time, a cascade of reports from areas where P. vivax ma-
laria is highly endemic conﬁ  rmed the clinical severity of 
the infections (7). However, to date, data are lacking on the 
distribution of severe P. vivax malaria, the relationship of 
patient age, and the identiﬁ  cation of possible risk factors. 
This study describes the clinical features of P. vivax ma-
laria in a case series of patients who were hospitalized in a 
tertiary care unit in the Brazilian Amazon and their clinical 
response to treatment with chloroquine.
The Study
The Tropical Medicine Foundation of Amazonas is a 
tertiary care center for infectious diseases in Manaus (3°8′S, 
60°1′W). In 2001 and 2002, a total of 13,056 cases of ma-
laria were diagnosed in this institution (11,251 P. vivax), 
representing 65.1% of the total cases from Manaus. During 
the same period, 358 (3.2%) patients with P. vivax malaria 
were hospitalized. A retrospective analysis was performed 
of case-patients who fulﬁ  lled the malaria severity criteria 
of the World Health Organization (WHO) (8). These pa-
tients had an exclusive diagnosis of P. vivax malaria by 
thick blood smear (reviewed 2 times by experienced mi-
croscopists) and PCR, according to the technique described 
elsewhere (9).
PCR was performed on whole blood from all patients 
with P. vivax malaria, conﬁ  rmed by microscopy and any 
P. falciparum severity criterion recommended by WHO. 
Blood specimens were routinely stored by the laboratory 
of the institution at –70°C. Full clinical information was 
available from the patients’ charts, and serologic tests for 
dengue virus, Leptospira spp., and hepatitis A, B, and C 
viruses were performed on available serum samples stored 
at –20°C.
Each patient was monitored for 28 days in outpatient 
clinics after beginning antimalarial treatment. Patients 
were routinely discharged only after parasitologic clear-
ance and clinical recovery. Until 2006, chloroquine was 
still prescribed for patients with severe cases at a dose of 
10 mg/kg on the ﬁ  rst day and 7.5 mg/kg on the second and 
third days, followed by primaquine (0.5 mg/kg/day for 7 
days), according to the Brazilian Ministry of Health guide-
lines. In 2006, WHO formally recommended the treatment 
of severe vivax malaria to be the same as that for severe 
falciparum malaria, because of the risk for an unrecognized 
mixed infection (8).
Seventeen patients were included in the analysis, and 
their clinical and laboratory data are shown in Tables 1 and 
2, respectively. All patients received chloroquine (orally or 
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tory distress syndrome (ARDS) (diffuse interstitial and al-
veolar inﬁ  ltrate by chest radiograph and partial O2 pressure 
40 mm Hg by arterial gas analysis) developed in patient 
11 two days after she received chloroquine, and she died 
3 days later. This patient had a negative thick blood smear 
from day 3 of treatment with choloroquine. The other 16 
patients were followed up after discharge until day 28. 
None had clinical symptoms of malaria, and all thick blood 
smears were negative at days 7, 14, and 28. 
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Table 1. Clinical characteristics of 17 hospitalized patients who had parasitologic and molecular diagnosis of Plasmodium vivax
infection, Manaus, Brazil, 2001–2002* 
Patient
no. Year  Age/sex WHO severity criterion 
Duration of 
disease, d 
Antimicrobial
drug use 
Erythrocyte 
transfusion
Concurrent 
condition ICU Death 
1 2001 2  y/F  Severe  anemia†  4 No Yes  – No No
2 2001  9 mo/M  Severe anemia†  10 No Yes  – No No
3 2001 3  y/F  Jaundice‡ 3 No No HAV No No
4 2001  60 y/F  Acute renal failure§  7 No No Arterial
hypertension 
No No
5 2001  1 mo/M  Severe anemia†  3 No Yes   –  No No
6 2001 40  y/M  Jaundice‡ 9 No No   –  No No
7 2001  80 y/M  Acute renal failure§  6 No No – No No
8 2002 7  y/M  Hemoglobinuria/
jaundice‡
4N o Y e s  – N o N o
9 2002  5 mo/M  Severe anemia†/ 
ARDS
3N o Y e s  – N o N o
10 2002 28  d/M  Jaundice‡ 5 No No – No No
11 2002 46  y/F  Severe  anemia†/ 
ARDS
5 No  Yes –  Yes  Yes 
12 2002 48  y/F  Jaundice‡ 7 No No – No No
13 2002 58  y/M  Jaundice‡ 12 No No Diabetes No No
14 2002 47  y/F  Jaundice‡ 8 No No – No No
15 2002  43 y/F  Shock¶/jaundice 4 Yes  Yes  – Yes  No
16 2002 34  y/M  Jaundice 10 No No – No No
17 2002 50  y/M  Jaundice 7 No No – No No
*WHO, World Health Organization; ICU, intensive care unit; HAV, hepatitis A virus; ARDS, acute respiratory distress syndrome (tachypnea, shortness of 
breath, and signs of hypoxemia). 
†Hemoglobin <7 g/dL in adults and <5 g/dL in children.  
‡Total bilirubin >3.0 mg/dL.  
§Creatinine >3.0 mg/dL.  
¶Systolic arterial tension <80 mm Hg despite fluid therapy. 
Table 2. Laboratory characteristics of 17 hospitalized patients who had parasitologic and molecular diagnosis of Plasmodium vivax
infection, Manaus, Brazil, 2001–2002* 
Patient
no.
No. asexual 
parasites/mm
3
Hemoglobin,
g/dL
Total leukocyte 
count,
cells/mm
3
Thrombocytes, 
cells/mm
3
Serum
creatinine,
mg/dL 
Serum bilirubin, 
total/conjugated,
mg/dL 
Serum
AST, IU/L 
Serum
ALT, IU/L 
1 7,566 3.6 9,700  97,000  0.5 1.1/0.4 50 30
2 28,847 4.5 9,100 30,000  0.6 1.3/0.5 40 34
3 1,100 9.5 5,500  143,000  0.4 6.6/5.6  760 1,233 
4 21,406 14.6 13,900 33,000  3.0 2.58/1.16  113 108
5 1,862 3.1 19,000  99,000  0.7 1.1/0.8 23 56
6 1,206 11.5 6,700 27,000  1.2 13.8/10.6  76 60
7 2,695 12.4 4,900 76,000  3.7 1.3/0.5 33 33
8 2,055 3.8 13,700  106,000  0.6 4.3/0.73  190 37
9 3,844 4.5 6,200  171,000  0.3 1.36/0.21  58 25
10 680 9.6 13,600 275,000  0.1 6.4/4.8  72 50
11 5,452 6.5 4,700  107,000  1.7 2.5/1.6 57 56
12 5,047 11.5 4,900 35,000  0.9 6.3/5.1 49 34
13 11,954 9.4 8,600 48,000  1.0 5.4/5.2 45 43
14 9,360 12.0 5,200 27,000  1.2 9.2/7.1 57 53
15 4,524 8.8 5,800  29,000  1.0 5.6/4.8 33 30
16 5,160 10.7 6,300 36,000  2.3 7.8/6.5 35 70
17 24,550 10.3 5,000  24,000  1.4 7.1/4.6  39 55
*WHO, World Health Organization; AST, aspartate aminotransferase; ALT, alanine aminotransferase. P. vivax Malaria, Brazilian Amazon
The patients in whom complications developed exhib-
ited a remarkably wide age range (28 days–80 years). This 
age range is similar to that seen in other case series from 
Latin America, such as in hospitalized children from Ven-
ezuela with severe anemia that required blood transfusions 
(10) and in adults from Rondônia (a state in the western 
Brazilian Amazon) who had severe anemia, jaundice, acute 
renal failure, ARDS, and shock (11). P. vivax malaria with 
ARDS has been reported in travelers who acquired the in-
fection in Manaus (12,13). The ﬁ  nding of severe anemia 
in 4 of 7 children highlights the relevance of this compli-
cation in P. vivax infection (Figure), as shown in a pro-
spective study from Papua, Indonesia (14). Nine patients 
sought treatment for cholestatic jaundice; for 8, jaundice 
was the only complication. The mechanisms involved are 
unknown.
The concomitant diagnosis of hepatitis A virus infec-
tion in patient 3 (Table 1) indicates that other infectious 
diseases should be excluded when characterizing severe 
P. vivax malaria. Also of note is the presence of thrombo-
cytopenia in 15/17 patients (none had clinical bleeding), 
which suggests that this hematologic complication may be 
a surrogate marker of severity.
Conclusions
The wide range of parasitemia found in our patients 
does not enable us to comment on the value of this variable 
as a determinant of severity. Sixteen patients recovered 
without the use of antimicrobial drugs; therefore, it is high-
ly improbable that bacterial sepsis was a factor for sever-
ity in our case series. In unstable transmission areas (<0.1 
autochthonous case per 1,000 persons per year), malaria 
in older patients may pose an additional problem because 
chronic diseases (e.g., arterial hypertension and diabetes) 
may predispose a patient to clinical decompensation.
In vivo chloroquine resistance was not detected in any 
of the cases that were followed up, despite recent conﬁ  rma-
tion of the phenomenon in this same locality (15). Because 
a reliable molecular marker of chloroquine resistance is 
lacking and parenteral artemisinin derivatives are recom-
mended for treatment of patients with severe P. vivax ma-
laria, studies that assess clinical severity and chloroquine 
resistance would be unethical. However, our ﬁ  ndings sug-
gest that chloroquine resistance would be a problem for 
individual patients and that the determinants of this resis-
tance need to be clariﬁ  ed. Clearly, areas with chloroquine-
resistant P. vivax also report severe P. vivax malaria, but we 
believe that these studies are not able to establish any ﬁ  rm 
causality. The ﬁ  nding of both phenomena in some areas 
may simply reﬂ  ect high transmission of this species.
Our retrospective review illustrates the spectrum of 
severe P. vivax malaria in Manaus, and these results par-
allel the increasing clinical severity described in malaria-
endemic areas such as Papua (Indonesia) and India. These 
severe P. vivax cases contribute to increased public health 
costs because of increased hospitalization and the need for 
intensive care and blood transfusions. The major complica-
tions in patients who required hospitalization were jaundice 
and severe anemia, although whether these complications 
were responsible for deaths is undetermined.
No clear severity criteria exist for P. vivax malaria. 
However, WHO criteria formerly deﬁ  ned for P. falcipar-
um malaria seem to be applicable to most of the severe P. 
vivax malaria cases reported in hospital-based studies in 
the literature. PCR should be performed to rule out mixed 
infections and other common infectious diseases so that 
reports from different parts of the world are comparable. 
Despite the small number of patients, our data corroborate 
previous ﬁ  ndings of severe disease found in areas where 
chloroquine-resistant P. vivax is being reported but suggest 
that establishing direct causality is not straightforward. We 
urgently need to know which clinical complications in P. 
vivax malaria are associated with death to validate sever-
ity criteria. A valid biomarker for chloroquine resistance 
would also enable associative studies to determine the as-
sociation between resistance and severity. 
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